• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Fragmented Incentives Shape US Biosimilar Adoption, Access

Commentary
Video

In part 2, James D. Chambers, PhD, MPharm, MSc, explains how fragmented US incentives slowed biosimilar uptake, with biologic coverage still varying.

Fragmented incentives across the US health care system may help explain why the country was slower than its peers to embrace biosimilars, according to James D. Chambers, PhD, MPharm, MSc, professor at Tufts Medical Center, in part 2 of an interview at the Academy of Managed Care Pharmacy Nexus 2026 meeting in San Diego, California.

Chambers, a panelist during the “Repositioning of Biosimilars: How Can the US Optimize Biosimilar Utilization to Improve Patient Health and Lower Total Cost of Care?” session, pointed to differing incentives among payers, pharmacy benefit managers, and providers that influence biosimilar adoption. Other countries typically have more centralized systems, with procurement processes that encourage competition among biosimilars. He added that better communication and education during the early days of biosimilars also helped those regions, whereas the US lagged behind.

Payer coverage of biologics also varies widely in the US, Chambers said. He cited the Specialty Drug Evidence and Coverage database, developed at Tufts Medicine to track how the largest payers cover specialty drugs. In ulcerative colitis, some plans never made a biologic the preferred therapy and instead required patients to step through conservative treatments, largely corticosteroids. Other plans made a biologic, either a biosimilar or the originator product, the first-line treatment.

“That variation has implications for patients, because it means they’ve got differing access to biologics, and also for providers, because providers then have to tailor their treatment choice not only to the patient’s clinical presentation but also to the patient’s insurance coverage,” Chambers said.

Greater transparency in coverage decision-making would help, he noted. However, because of rebates and because insurers negotiate with manufacturers separately, Chambers said this variation may be here to stay, both for biosimilars and for specialty therapies more broadly.

Looking ahead, managed care pharmacists are well positioned to lead a more holistic approach. Chambers said he hopes that a biologic’s loss of exclusivity will eventually prompt a broader reassessment of the evidence, rather than simply a contracting event. That reassessment would include clinical guidelines, the economics of treating the disease with biologics, and existing utilization management and access requirements.

“As I said, pharmacists are perfectly placed to do this, to ensure that we’re really providing patients with adequate and appropriate access to biologics,” Chambers concluded. “Hopefully, that is in better alignment with some of the clinical guidelines out there.”

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Juliana M. Reed, MS
© 2026 MJH Life Sciences

All rights reserved.